What's Hot
View all perspectives
Dr. John Cush RheumNow
2 years 5 months ago
Watch: EULAR Recommendations for ANCA Vasculitis
Dr. Eric Dein reviews the session held on updates to recommendations for ANCA Vasculitis, presented at the #EULAR2022 meeting in June.
https://t.co/1nr0tVIJpn https://t.co/kq0Id7PxyW
Dr. John Cush RheumNow
2 years 5 months ago
A Big Leap in Modulating Rheumatoid Disease
Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic.
https://t.co/QHK7c3Qhz6 https://t.co/jFR9wDCD8o
Aurelie Najm AurelieRheumo
2 years 5 months ago
CTD associated ILD 🫁:
lncRNA ENST00000604692 detected in PBMCs is associated with CTD-ILD and can distinguish SSc-
ILD and RA-ILD vs. non ILD patients with AUC 0.79.
As many lncRNA, unknown if biomarker only or has a pathogenic role.
@RheumNow OP0114 #EULAR2022 https://t.co/sR4GmaMkXD
Aurelie Najm AurelieRheumo
2 years 5 months ago
Lung 🫁 cancer incidence and RA
44000+ RA (EIRA prospective cohort) and 216000+ matched Ctrls Swedish registries
📍56 per 100,000
📍HR 1.77 (adjusted for smoking 🚬)
📍Risk in RA + smoking 7x higher
📍Risk 2x in Sero+ vs. sero-
No data on ttmt
#EULAR2022 @RheumNow POS0061 https://t.co/c7eh3icW2c
Aurelie Najm AurelieRheumo
2 years 5 months ago
B-cell depletion w/ RTX ttmt is FcγR dependant & affected by FcγRs variants 🧬
FCGR3A-158V:
*encodes the allotype ⬆️ affinity for IgG1
*is associated w/ clinical and biological responses in RA and SLE.
A new way to stratify pts for anti-CD20 therapy?
@Yuz6Yusof #EULAR2022 OP0190 https://t.co/GPiaQXaF71
Dr Qasim Akram (South Manchester Rheumatologist) DrQasimAkram
2 years 5 months ago
Great meeting @RheumNow. He does a great job of educating Rheumatologists around the world especially through his podcast. Great discussion on the usefulness of ultrasound for Rheumatologists #EULAR2022 https://t.co/0hw7mpX8dm
Richard Conway RichardPAConway
2 years 5 months ago
Pascual et al. Anti-TIF1gamma and cancer risk in DM and non-DM. Cancer in 60% of DM and 21% of non-DM patients with Anti-TIF1gamma https://t.co/OxKdlmDBBD
Richard Conway RichardPAConway
2 years 5 months ago
Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu
Robert B Chao, MD doctorRBC
2 years 5 months ago
Baseline molecular differences noted in PsA patients who are TNFi naive and incomplete responders. Elevated IL-22 expression may suggest increased involvement of IL-23 pathway in TNF-IR pts. @RheumNow #EULAR2022 ABST#POS0074
Richard Conway RichardPAConway
2 years 5 months ago
Vadillo et al. Clinical course in IPAF (ping @leticiakawano ) . Most frequent females in 60s. Arthritis, raynauds most common features. Most NSIP. 50% PFT deterioration 16 months. UIP, baseline fibrosis, mod/high ANA titre assoc progression @RheumNow #EULAR2022 POS1427 https://t.co/qk9zK90Wuk
Robert B Chao, MD doctorRBC
2 years 5 months ago
Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts.
@RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC
Richard Conway RichardPAConway
2 years 5 months ago
Rahman et al. 2 year results on dactylitis/enthesitis from Discover-2 study guselkumab. Sustained improvements seen over time @RheumNow #EULAR2022 POS1028 https://t.co/VZhw6g4kCB
TheDaoIndex KDAO2011
2 years 5 months ago
“I would not use rituximab unless I have to; use it in vasculitis/SLE nephritis, but for RA, you have other options.” – Prof. I McGinnes #EULAR2022 @rheumnow
Richard Conway RichardPAConway
2 years 5 months ago
Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consistent with those expected for PsO/PsA populations. @RheumNow #EULAR2022 POS1023 https://t.co/yv5fFbUSI6
Eric Dein ericdeinmd
2 years 5 months ago
Kimme Hyrich:
💉Risks of autoimmune flare is very low (3-5%)
💉Flares are mild when present after COVID-19 vaccination
Most unvaccinated patients did NOT identify as "anti-vax"... number 1 reason is concerns about their health
#EULAR2022 @RheumNow @rheum_covid https://t.co/Ogn0raifPd
Poster Hall